TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29355055

Group type: EXPERIMENTAL
Intervention: Various recruitment methods (trial registration, posters/flyers, print publications, Internet, social media, radio, databases, referrals)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Recruitment monitoring and adjustment of procedures
Number of subjects: 584
Study: 27271718

Group type: EXPERIMENTAL
Intervention: LA‐TME
Number of subjects: 45

Group type: COMPARATOR
Intervention: TA‐TME
Number of subjects: 45
Study: 24673051

Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 110
Study: 22307524

Group type: EXPERIMENTAL
Intervention: Water-dispersible hesperetin, 150 mg single dose
Number of subjects: 0
Study: 20813872

Group type: EXPERIMENTAL
Intervention: MT MR imaging in HD gene carriers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 17912223

Group type: EXPERIMENTAL
Intervention: Convective dialytic therapies (hemodiafiltration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diffusive techniques (hemodialysis)
Number of subjects: 0
Study: 16262543

Group type: EXPERIMENTAL
Intervention: Psychological interventions with detailed action plans and barrier-focused mental strategies
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Psychological interventions with a weekly diary kept for 6 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard care rehabilitation program
Number of subjects: 240
Study: 12011290

Group type: EXPERIMENTAL
Intervention: Oral Delta(9)-Tetrahydrocannabinol (THC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cannabis sativa plant extract
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10450481

Group type: EXPERIMENTAL
Intervention: Five second stretching group (holding each stretch for 5 seconds, 9 times, total 45 seconds per exercise)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fifteen second stretching group (holding each stretch for 15 seconds, 3 times, total 45 seconds per exercise)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison between treatment groups
Number of subjects: 24
Study: 7788007

Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) treatment for a period of 2.8 (2.8) years with a mean daily dose of 77 (18) micrograms/m2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) treatment
Number of subjects: 16
Study: 28426515

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 minutes targeting the motor cortex bilaterally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cathodal tDCS (2 mA for 20 minutes targeting the motor cortex bilaterally)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS (2 mA for 20 minutes targeting the motor cortex bilaterally)
Number of subjects: 10
Study: 30664020

Group type: EXPERIMENTAL
Intervention: Surgical fecal stream diversion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rectal samples
Number of subjects: 28
Study: 29031121

Group type: EXPERIMENTAL
Intervention: Unlimited access to BRECONDA with usual care
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study: 27062800

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue
Number of subjects: 349

Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 349
Study: 23427865

Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.01 mL/min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.05 mL/min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.1 mL/min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infusion rate of 0.5 mL/min
Number of subjects: 24
Study: 21378358

Group type: EXPERIMENTAL
Intervention: SLNB plus ALNS (Group B)
Number of subjects: 112

Group type: COMPARATOR
Intervention: SLNB alone (Group A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 19397849

Group type: EXPERIMENTAL
Intervention: Haloperidol (1.25-5.0 mg daily)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-2.0 mg daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17504683

Group type: EXPERIMENTAL
Intervention: Isoniazid for six months (6H)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Rifampin and isoniazid for three months (3RH)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Rifampin and pyrazinamide for two months (2RZ)
Number of subjects: 316
Study: 15244235

Group type: EXPERIMENTAL
Intervention: Likert scale
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Numeric VAS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Simple VAS
Number of subjects: 120

Group type: COMPARATOR
Intervention: All response options
Number of subjects: 120
Study: 11551130

Group type: EXPERIMENTAL
Intervention: Cisplatin-containing regimens concurrent with radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT-compatible applicators for intracavitary radiation, CT simulation, and three-dimensional treatment planning for EBRT
Number of subjects: 0
Study: 9674079

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (matched patients who did not commit suicide)
Number of subjects: 34
Study: 8011000

Group type: EXPERIMENTAL
Intervention: Fluorohydrocarbons-free glyceryl trinitrate pump spray with low ethanol content (TL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluorocarbon-free GTN pump spray with high ethanol content (TH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fluorocarbon-containing GTN spray (R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo spray (TL-matched placebo)
Number of subjects: 0
Study: 2910090

Group type: EXPERIMENTAL
Intervention: 125 mg of vancomycin orally four times daily for an average of 10 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: 500 mg of vancomycin orally four times daily for an average of 10 days
Number of subjects: 46
Study: 376236

Group type: EXPERIMENTAL
Intervention: Low dose Heparin therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trasylol
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (patients who died)
Number of subjects: 35
Study: 31816306

Group type: EXPERIMENTAL
Intervention: Outpatient ibuprofen plus acetaminophen (nonopioid, n=85)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Outpatient ibuprofen plus hydrocodone‐acetaminophen (opioid, n=85)
Number of subjects: 170
Study: 30640303

Group type: EXPERIMENTAL
Intervention: Lower-load resistance training (LL; n = 14, loads for 30-35 repetitions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Higher-load resistance training (HL; n = 18, loads for 8-10 repetitions)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lower-load resistance training (LL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Higher-load resistance training (HL)
Number of subjects: 32
Study: 28824041

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/day + Teneligliptin 20 mg/day
Number of subjects: 30
Study: 25217230

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy in primary therapy of PCNSL
Number of subjects: 526
Study: 23725788

Group type: EXPERIMENTAL
Intervention: Prone sleeping position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Supine sleeping position
Number of subjects: 10
Study: 21343556

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg (subcutaneous, monthly)
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg (intravenous, dose adjusted for renal impairment)
Number of subjects: 1776
Study: 18302468

Group type: EXPERIMENTAL
Intervention: Attachments only (AO)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interproximal reduction only (IO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neither attachments nor interproximal reduction (N)
Number of subjects: 31
Study: 16236778

Group type: EXPERIMENTAL
Intervention: Adapting RA afferent fibers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static or vibrating gratings with varying spatial period and vibratory frequency
Number of subjects: 0
Study: 15057391

Group type: EXPERIMENTAL
Intervention: Etching with 36% phosphoric acid gel - Conditioner 36 (Dentsply) for 20 s, followed by water rinse for 15 s
Number of subjects: 10

Group type: COMPARATOR
Intervention: Etching with NRC - Non Rinse Conditioner (Dentsply) for 20 s, followed by air drying for 15 s
Number of subjects: 10
Study: 10711472

Group type: EXPERIMENTAL
Intervention: Intermittent compression pump
Number of subjects: 16

Group type: COMPARATOR
Intervention: Compression bandages
Number of subjects: 16
Study: 9176034

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (200 mg zinc sulphate, 500 mg ascorbic acid, 600 mg alpha-tocopherol, 30 mg beta-carotene daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 40
Study: 1376842

Group type: EXPERIMENTAL
Intervention: Isradipine (1.25-2.5 mg twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2858421

Group type: EXPERIMENTAL
Intervention: Reproterol (0.28 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol (0.1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31318863

Group type: EXPERIMENTAL
Intervention: Operative treatment with a locking plate
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 88
Study: 29743380

Group type: EXPERIMENTAL
Intervention: DAPT plus 14-day cilostazol (Carrier/DAPT+Cilostazol)
Number of subjects: 128

Group type: COMPARATOR
Intervention: DAPT (Carrier/DAPT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: DAPT (Noncarrier/DAPT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Discontinuation of cilostazol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Carrier/DAPT+Cilostazol
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Withdrawal of cilostazol
Number of subjects: 128
Study: 26692120

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 25113414

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 50
Study: 22670598

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg every 6 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 20492655

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin 20 mg (EZ + simva 10/20 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 93
Study: 19167588

Group type: EXPERIMENTAL
Intervention: ezetimibe + pravastatin 10 to 40 mg/d
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: ezetimibe + simvastatin 10 to 80 mg/d
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: ezetimibe + pravastatin
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: ezetimibe + simvastatin
Number of subjects: 795
Study: 15278749

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day) for 12 months
Number of subjects: 80
Study: 12365905

Group type: COMPARATOR
Intervention: Optisol-GS
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chen Medium (CM)
Number of subjects: 90
Study: 9722253

Group type: EXPERIMENTAL
Intervention: MM + MNF (multi-nutrient fortification of mother's milk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-MM (breastfeeding after mother's milk)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-FF (formula feeding after hospital discharge)
Number of subjects: 0
Study: 7863047

Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Oxygen Therapy (CAOT) - Group B
Number of subjects: 58

Group type: COMPARATOR
Intervention: No Continuous Ambulatory Oxygen Therapy (CAOT) - Group A
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison between Group B and Group A
Number of subjects: 58
Study: 2768606

Group type: EXPERIMENTAL
Intervention: 10-week interpersonal transaction (IT) group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 10-week process group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Wait list condition
Number of subjects: 65
Study: 172561

Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated decavalent rhinovirus vaccine 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated decavalent rhinovirus vaccine 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29672740

Group type: EXPERIMENTAL
Intervention: Vadadustat 300 mg once daily (QD)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Vadadustat 450 mg once daily (QD)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Vadadustat 450 mg thrice weekly (TIW)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall (all dose cohorts)
Number of subjects: 94
Study: 29633515

Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel (35 mg/m2 weekly or 75 mg/m2 every 3 weeks)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Continuous docetaxel (35 mg/m2 weekly or 75 mg/m2 every 3 weeks)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Intermittent docetaxel
Number of subjects: 187

Group type: COMPARATOR
Intervention: Continuous docetaxel
Number of subjects: 187
Study: 27021377

Group type: EXPERIMENTAL
Intervention: 14 Gy external beam radiation (EBR)
Number of subjects: 155

Group type: COMPARATOR
Intervention: 0 Gy external beam radiation (EBR)
Number of subjects: 155
Study: 25073921

Group type: EXPERIMENTAL
Intervention: Buffered saline solution
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 3014

Group type: COMPARATOR
Intervention: Blood solution
Number of subjects: 3014
Study: 22442773

Group type: EXPERIMENTAL
Intervention: Duralay II with Method 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GC Pattern Resin with Method 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GC Pattern Resin with Method 2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GC Pattern Resin with Method 3
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duralay II with Method 2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duralay II with Method 3
Number of subjects: 60
Study: 20606542

Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Classical radical hysterectomy
Number of subjects: 31
Study: 17511155

Group type: EXPERIMENTAL
Intervention: Compositae salviae dropping pill (CSDP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Simvastatin (Control)
Number of subjects: 81
Study: 15625210

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 63
Study: 11755280

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 13955

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 13955
Study: 10357349

Group type: EXPERIMENTAL
Intervention: Controlled ventilation (CV group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Spontaneous breathing (SB group, n = 15)
Number of subjects: 30
Study: 7488576

Group type: EXPERIMENTAL
Intervention: Scanning laser ophthalmoscope (SLO) imaging at 590 nm, 670 nm, and 830 nm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Scanning laser ophthalmoscope (SLO) imaging
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Confocal aperture in SLO imaging
Number of subjects: 19
Study: 2021797

Group type: EXPERIMENTAL
Intervention: Short overall treatment time (less than or equal to 4 weeks) with 5 fractions per week regime
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Short overall treatment time (less than or equal to 4 weeks)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Long overall treatment time (greater than 4 weeks)
Number of subjects: 602
Study: 7034788

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Benson's Relaxation Response (BRR)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No Treatment (NT)
Number of subjects: 77
Study: 31762338

Group type: EXPERIMENTAL
Intervention: Nitrox40
Number of subjects: 13

Group type: COMPARATOR
Intervention: Air
Number of subjects: 13
Study: 31329183

Group type: EXPERIMENTAL
Intervention: Rehabilitation measures in the Department of Medical Rehabilitation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group in the Department of Neurology
Number of subjects: 116
Study: 28616417

Group type: EXPERIMENTAL
Intervention: Simulation training (role-playing and moulage training)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral training (lecture and short movie)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 51
Study: 25885095

Group type: EXPERIMENTAL
Intervention: Happy Heart educational program (11-week group meetings of nutritional education)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard outpatient care (control group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Happy Heart educational program
Number of subjects: 37
Study: 25371147

Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF)
Number of subjects: 1347
Study: 22265386

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound+lidocaine
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound+lidocaine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (sham ultrasound+lidocaine)
Number of subjects: 93
Study: 20370860

Group type: EXPERIMENTAL
Intervention: Geri‐FITT
Number of subjects: 717

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 717
Study: 17369796

Group type: EXPERIMENTAL
Intervention: Carbon fiber eccentric chainring (EC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard chainring (SC)
Number of subjects: 11
Study: 16328746

Group type: EXPERIMENTAL
Intervention: School-based intervention for social anxiety disorder
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 35
Study: 11874410

Group type: EXPERIMENTAL
Intervention: Low-dose oral hydrocortisone replacement (15 mg at 0800, 5 mg at 1700)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Physiological hydrocortisone infusion (PHI)
Number of subjects: 15
Study: 10213464

Group type: EXPERIMENTAL
Intervention: CT + natural IFN‐alpha (3 MU three times a week i.m.)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: CT + recombinant IFN alpha‐2a (3 MU three times a week i.m.)
Number of subjects: 219

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 219
Study: 7562888

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nifedipine-GITS 30 mg
Number of subjects: 4
Study: 2161295

Group type: EXPERIMENTAL
Intervention: Carboplatin 300 or 400 mg/m2 every 4 weeks
Number of subjects: 129
Study: 7315769

Group type: EXPERIMENTAL
Intervention: 5 mg fluoride as sodium fluoride in divided doses with meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg fluoride as sodium fluoride in divided doses with meals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no fluoride supplements)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mg fluoride as sodium fluoride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg fluoride as sodium fluoride
Number of subjects: 0
Study: 31407212

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 16

Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 16
Study: 28771964

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 199
Study: 26481215

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² and bevacizumab 15 mg/kg (Level 0 cohort)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Docetaxel 50 mg/m² and bevacizumab 15 mg/kg (Level 1 cohort)
Number of subjects: 21
Study: 22873656

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus metronidazole (375 mg amoxicillin and 500 mg metronidazole, three times daily for 7 days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 17175037

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no orlistat)
Number of subjects: 22
Study: 15309002

Group type: EXPERIMENTAL
Intervention: Right atrial septal pacing
Number of subjects: 124

Group type: COMPARATOR
Intervention: Right atrial appendage pacing
Number of subjects: 124
Study: 11099993

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 9183841

Group type: EXPERIMENTAL
Intervention: Provision of music
Number of subjects: 0
Study: 8473551

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of clentiazem (20 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral (PO) administration of clentiazem (80 mg)
Number of subjects: 24
Study: 2869591

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms bolus followed by 300 micrograms/hr infusion)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (150 mm of NaCl)
Number of subjects: 4
Study: 30509095

Group type: EXPERIMENTAL
Intervention: Conventional ultrasound and CEUS
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: p16 protein expression in para‐carcinoma tissues
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: p16 positive and negative groups
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Correlation of p16 expression with ultrasound parameters
Number of subjects: 84
Study: 28595285

Group type: EXPERIMENTAL
Intervention: Chemotherapy with bevacizumab
Number of subjects: 326

Group type: COMPARATOR
Intervention: Chemotherapy without bevacizumab (Control)
Number of subjects: 326
Study: 26552426

Group type: EXPERIMENTAL
Intervention: Tree Theme Method (TTM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 0